Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge.
TransMedics Group (TMDX) has drawn investor attention after recent trading saw the stock close at US$129.61, with short term returns under pressure even as longer term performance and current fundamentals invite closer scrutiny.
See our latest analysis for TransMedics Group.
The recent 1 day share price decline of 7.47%, alongside a 7 day share price return of negative 10.77%, contrasts with a 1 year total shareholder return of 92.13%. This pattern suggests strong longer term momentum even as short term sentiment cools.
If this volatility has you looking beyond a single name, it could be a useful moment to scan 32 healthcare AI stocks as a way to spot other potential opportunities in the sector.
With TransMedics Group showing a value score of 5, an indicated intrinsic discount of about 46% and a current price below the average analyst target, the key question is whether this signals a genuine opportunity or whether the market is already pricing in future growth.
With TransMedics Group last closing at $129.61 against a widely followed fair value estimate of $144.20, the current price sits below what that narrative considers reasonable, setting up a clear valuation gap for investors to weigh.
Development of a recurring, service-driven revenue model, including logistics, digital ecosystem, and service contracts, enables more predictable and stable cash flows, which improves operating leverage and could drive higher long-term net margins.
Curious how a recurring service model, richer margins, and future earnings expectations all fit together here? The most followed narrative leans heavily on those moving parts, but the exact revenue path, margin profile and valuation multiple it uses might surprise you.
Result: Fair Value of $144.20 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, this depends on continued clinical success and smooth international expansion. Regulatory hurdles or slower adoption could quickly challenge those margin and growth assumptions.
Find out about the key risks to this TransMedics Group narrative.
Seeing both enthusiasm and concern in the story so far, you might want to move quickly and weigh the balance for yourself with 4 key rewards and 1 important warning sign.
If you stop with just one stock, you risk missing other opportunities. Use the tools available and let data rich shortlists do some of the heavy lifting for you.